Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/43070
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Henríquez-Hernández, L. A. | |
dc.contributor.author | Flores-Morales, A. | |
dc.contributor.author | Santana-Farré, R. | |
dc.contributor.author | Axelson, M. | |
dc.contributor.author | Nilsson, P. | |
dc.contributor.author | Norstedt, G. | |
dc.contributor.author | Fernández-Pérez, L. | |
dc.date.accessioned | 2018-11-21T12:22:16Z | - |
dc.date.available | 2018-11-21T12:22:16Z | - |
dc.date.issued | 2007 | |
dc.identifier.issn | 0022-3565 | |
dc.identifier.uri | http://hdl.handle.net/10553/43070 | - |
dc.description.abstract | Estrogens cause intrahepatic cholestasis in susceptible women during pregnancy, after administration of oral contraceptives, or during postmenopausal hormone replacement therapy. 17 alpha-Ethinylestradiol ( EE) is a synthetic estrogen widely used to cause experimental cholestasis in rodents with the aim of examining molecular mechanisms involved in this disease. EE actions on the liver are thought to be mediated by estrogen receptor alpha ( ER alpha) and pituitary hormones. We tested this hypothesis by analyzing metabolic changes induced by EE in livers from hypophysectomized ( HYPOX) and hypothyroid rats. Microarray studies revealed that the number of genes regulated by EE was increased almost 4-fold in HYPOX rat livers compared with intact males. Little overlap was apparent between the effects of EE in intact and HYPOX rats, demonstrating that pituitary hormones play a critical role in the hepatic effects of EE. Consistently, hypophysectomy protects the liver against induction by EE of serum bilirubin and alkaline phosphatase, two markers of cholestasis and hepatotoxicity and modulates the effects of EE on several genes involved in bile acid homeostasis ( e. g., FXR, SHP, BSEP, and Cyp8b1). Finally, we demonstrate a novel mechanism of action of EE through binding and negative regulation of glucocorticoid receptor-mediated transcription. In summary, pituitary- and ER alpha- independent mechanisms contribute to development of EE-induced changes in liver transcriptome. Such mechanisms may be relevant when this model of EE-induced cholestasis is evaluated. The observation that the pharmacological effects of estrogen in liver differ in the absence or presence of the pituitary could be clinically relevant, because different drugs that block actions of pituitary hormones are now available. | |
dc.publisher | 0022-3565 | |
dc.relation.ispartof | Journal of Pharmacology and Experimental Therapeutics | |
dc.source | Journal of Pharmacology and Experimental Therapeutics[ISSN 0022-3565],v. 320, p. 695-705 | |
dc.subject.other | Small Heterodimer Partner | |
dc.subject.other | Growth-Hormone | |
dc.subject.other | Gene-Expression | |
dc.subject.other | In-Vivo | |
dc.subject.other | Cholesterol 7-Alpha-Hydroxylase | |
dc.subject.other | Estrogen-Receptor | |
dc.subject.other | Bile-Acids | |
dc.subject.other | Sterol 12-Alpha-Hydroxylase | |
dc.subject.other | Microarray Data | |
dc.subject.other | Target Genes | |
dc.title | Role of pituitary hormones on 17α-ethinylestradiol-induced cholestasis in rat | |
dc.type | info:eu-repo/semantics/Article | es |
dc.type | Article | es |
dc.identifier.doi | 10.1124/jpet.106.113209 | |
dc.identifier.scopus | 33846446700 | - |
dc.identifier.isi | 000243605400024 | |
dc.contributor.authorscopusid | 15829708200 | |
dc.contributor.authorscopusid | 57203543352 | |
dc.contributor.authorscopusid | 15830358800 | |
dc.contributor.authorscopusid | 7005878959 | |
dc.contributor.authorscopusid | 7202850334 | |
dc.contributor.authorscopusid | 7006397634 | |
dc.contributor.authorscopusid | 6506777525 | |
dc.description.lastpage | 705 | |
dc.description.firstpage | 695 | |
dc.relation.volume | 320 | |
dc.type2 | Artículo | es |
dc.contributor.daisngid | 465624 | |
dc.contributor.daisngid | 617657 | |
dc.contributor.daisngid | 3808417 | |
dc.contributor.daisngid | 191093 | |
dc.contributor.daisngid | 190646 | |
dc.contributor.daisngid | 178539 | |
dc.contributor.daisngid | 795544 | |
dc.contributor.wosstandard | WOS:Henriquez-Hernandez, LA | |
dc.contributor.wosstandard | WOS:Flores-Morales, A | |
dc.contributor.wosstandard | WOS:Santana-Farre, R | |
dc.contributor.wosstandard | WOS:Axelson, M | |
dc.contributor.wosstandard | WOS:Nilsson, P | |
dc.contributor.wosstandard | WOS:Norstedt, G | |
dc.contributor.wosstandard | WOS:Fernandez-Perez, L | |
dc.date.coverdate | Febrero 2007 | |
dc.identifier.ulpgc | Sí | es |
dc.description.jcr | 4,003 | |
dc.description.jcrq | Q1 | |
dc.description.scie | SCIE | |
item.fulltext | Sin texto completo | - |
item.grantfulltext | none | - |
crisitem.author.dept | GIR IUIBS: Medio Ambiente y Salud | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Clínicas | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | GIR IUIBS: Farmacología Molecular y Traslacional | - |
crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.dept | Departamento de Ciencias Clínicas | - |
crisitem.author.orcid | 0000-0003-3237-0316 | - |
crisitem.author.orcid | 0000-0002-0828-8921 | - |
crisitem.author.orcid | 0000-0001-7802-465X | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
crisitem.author.fullName | Henríquez Hernández, Luis Alberto | - |
crisitem.author.fullName | Flores Morales,Amilcar | - |
crisitem.author.fullName | Fernández Pérez, Leandro Francisco | - |
Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.